[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto Nacional de Cardiologia Ignacio Chavez\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":141},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,82,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100632251","phase-4-multicenter-trial-of-antithrombotic-strategies-in-acute-coronary-syndrome-with-coronary-artery-ectasia-100632251",false,"NCT07511257","Multicenter Trial of Antithrombotic Strategies in Acute Coronary Syndrome With Coronary Artery Ectasia","Dual Antiplatelet Therapy Versus Antiplatelet Monotherapy Plus Anticoagulation in Patients With Acute Coronary Syndrome and Coronary Artery Ectasia: A Multicenter Randomized Clinical Trial","OVER-TIME II","Inclusion Criteria:\n\n* Adults aged 18 to 80 years, of either sex, hospitalized with acute coronary syndrome (ACS) with or without ST-segment elevation.\n* Recent ACS within 7 days prior to enrollment, defined by all of the following:\n* Clinical presentation consistent with acute coronary syndrome.\n* Elevated high-sensitivity cardiac troponin above the 99th percentile.\n* Presence or absence of persistent ST-segment elevation.\n* Coronary artery ectasia in the culprit coronary artery, defined by all of the following:\n* The presence of ectasia will be determined by agreement of two expert interventional cardiologists, and will be confirmed by quantitative coronary angiography (QCA).\n* Identification of a culprit artery consistent with the electrocardiographic territory involved (in cases with ST-segment elevation) or with angiographic features suggestive of an atherothrombotic event, such as the presence of thrombus or reduced coronary flow.\n* Hospital admission lasting more than 24 hours.\n* Management with either percutaneous coronary intervention or medical therapy, as determined by the treating medical team. Intracoronary interventions such as stent implantation, balloon angioplasty, or thrombus aspiration are permitted.\n* Ability and willingness to provide written informed consent and to participate in the study.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Current indication for temporary or long-term anticoagulation therapy at the time of enrollment.\n* Severe chronic kidney disease, defined as KDIGO stage G4 or higher (estimated glomerular filtration rate \\[eGFR\\] \\\u003C30 mL\u002Fmin\u002F1.73 m²).\n* Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m² at hospital discharge.\n* History of major bleeding, active bleeding, or high bleeding risk, including but not limited to gastrointestinal bleeding, intracranial hemorrhage, or other conditions considered by the treating physician to confer a high risk of bleeding.\n* Advanced heart failure, defined as left ventricular ejection fraction (LVEF) \\\u003C30% plus at least one of the following:\n* More than two hospitalizations or unplanned emergency department visits for heart failure in the past year, or\n* NYHA functional class III or IV symptoms despite optimal medical therapy at enrollment or within the previous 3 months.","ALL","18 Years","80 Years",{"count":21,"type":22},326,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Coronary artery ectasia (CAE) is a condition in which a coronary artery becomes abnormally dilated, measuring at least 50% larger than the adjacent normal segment. Although relatively uncommon, CAE is clinically important because it can lead to abnormal blood flow and increase the risk of blood clot formation. Patients with CAE are at higher risk of angina, myocardial infarction, and complications during coronary interventions. Despite these risks, the optimal antithrombotic treatment for patients with acute coronary syndrome (ACS) and CAE remains uncertain.\n\nDual antiplatelet therapy (aspirin plus clopidogrel) is currently the most commonly used treatment. However, the abnormal blood flow patterns observed in CAE may promote clot formation through mechanisms that could potentially be better addressed with anticoagulant therapy.\n\nThe OVER-TIME II trial is a multicenter randomized clinical trial designed to compare two antithrombotic strategies in patients with ACS and CAE: standard dual antiplatelet therapy versus antiplatelet monotherapy combined with anticoagulation. The study aims to determine whether the addition of anticoagulation reduces major cardiovascular events without significantly increasing bleeding risk.",[28,29,30,31],"Coronary Artery Ectasia","Acute Coronary Syndromes (ACS)","STEMI - ST Elevation Myocardial Infarction","NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)",[28,33,34,35],"Acute Coronary Syndrome","Anticoagulation","Dual Antiplatelet Therapy","RECRUITING","2026-04-06",{"date":39,"type":40},"2026-04-09","ACTUAL",{"date":42,"type":40},"2026-02-11",{"date":44,"type":22},"2029-06",{"name":46,"class":47},"Instituto Nacional de Cardiologia Ignacio Chavez","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100583869","cardiac-rehabilitation-program-on-the-prevention-of-cardiotoxicity-in-breast-cancer-patients-undergoing-treatment-with-anthracyclines-andor-trastuzumab-100583869","NCT06881940","Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and\u002For Trastuzumab","Rationale and Design of a Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and\u002For Trastuzumab: A Randomized, Active Control Group, Open-Label Trial","CARPTOX-BC","Inclusion Criteria:\n\n* Women aged between 18 and 70 years will be considered eligible.\n* Active residents of any municipality within Mexico City and the surrounding metropolitan area will qualify, conditioned that their maximum travel time from their residence to our recruitment center does not exceed three hours using private or public transportation. This criterion is established to ensure adherence to the protocol and availability for participation in the required interventions and assessments throughout the study.\n* Patients diagnosed with early-stage or locally advanced breast cancer (stages I, II, or III, according to the TNM classification-Tumor, Node, Metastasis) who will undergo treatment with anthracyclines and\u002For adjuvant\u002Fneoadjuvant anti-HER2 therapy will be included. Participants must be scheduled to receive pharmacological treatment, ensuring that the study focuses on a population undergoing specific therapies for breast cancer management.\n* Candidates must have the capacity, availability, and willingness to participate in an aerobic and resistance exercise program. Participants are required to possess both the physical ability and the willingness to actively engage in a structured exercise program, which includes aerobic and resistance activities essential to the study's objectives.\n* Patients will provide informed written consent to participate in the study. To uphold ethical research principles and ensure the protection of participants' rights, all patients must voluntarily give their informed consent after receiving comprehensive information regarding the study's objectives, procedures, benefits, and potential risks.\n\nExclusion Criteria:\n\n* Metastatic disease: Individuals with medical or imaging evidence of metastasis to any peripheral organ.\n* Cardiovascular disease: Patients with a self-reported history of cardiovascular conditions, such as heart failure or uncontrolled hypertension, that may limit their ability to safely engage in physical activity. Additionally, those with peripheral arterial disease or valvular heart disease will not be eligible.\n* Ischemic heart disease: Patients with a history of ischemic heart disease.\n* Neurological disorders: Individuals with self-reported neurological diseases that significantly impair coordination, balance, or motor control, such as advanced Parkinson's disease, late-stage multiple sclerosis, or paralysis, making physical activity unsafe.\n* Musculoskeletal conditions: Patients with self-reported musculoskeletal injuries or disorders that hinder physical activity, including fractures within the last five years, moderate to severe sprains, tendinitis, or severe arthritis.\n* Uncontrolled systemic comorbidities: Individuals with decompensated systemic conditions, including heart failure, chronic kidney disease, or poorly controlled diabetes, will be excluded.\n* Severe respiratory diseases: Patients with severe respiratory conditions that prevent physical exercise participation.\n* Physical limitations: Individuals with mobility impairments or conditions requiring constant assistance for basic physical activities, such as those using assistive devices (e.g., wheelchairs, walkers) or with limb amputations, will not be eligible for participation.\n* Severe psychiatric disorders: Patients with uncontrolled psychiatric conditions, including schizophrenia, severe bipolar disorder, or major depressive disorder, that may interfere with their ability to actively participate in a supervised exercise program.\n\nElimination Criteria:\n\n* Voluntary withdrawal from the protocol.\n* Development of severe cardiotoxicity requiring pharmacological treatment.\n* Adverse reactions to chemotherapeutic agents.\n* Disease progression according to the TNM classification during treatment.\n* Failure to complete at least 80% of the prescribed adjuvant or neoadjuvant oncological treatment.\n* Occurrence of adverse events during the study, such as falls or injuries.\n* Death during the study period.\n* Any accident related to the exercise protocol, including falls, sprains, or fractures.","FEMALE","70 Years",{"count":60,"type":22},284,[62],"NA","This study aims to evaluate the effectiveness of a cardiac rehabilitation protocol, incorporating aerobic and resistance exercise, in reducing the incidence of cardiotoxicity in breast cancer patients receiving treatment with anthracyclines and\u002For trastuzumab through a randomized, active control group, open-label clinical trial.",[65],"Cancer Therapy-Related Cardiac Dysfunction",[67,68,69,70,71],"Rehabilitation","Breast Neoplasms","Cardiotoxicity","Trastuzumab","Anthracyclines","NOT_YET_RECRUITING","2025-03-14",{"date":75,"type":40},"2025-03-18",{"date":77,"type":22},"2025-04-01",{"date":79,"type":22},"2029-12-01",{"name":46,"class":47},2,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":113,"locationsCount":48},"100556147","impact-of-nicotinamide-riboside-nr-on-kidney-function-in-patients-undergoing-cardiac-surgery-100556147","NCT06521307","Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery","Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery.A Randomized Controlled Pilot Study","AKI-RCT","Inclusion Criteria:\n\n* Heart valve replacement surgery\n* Sign of informed consent\n\nExclusion Criteria:\n\n* Allergy to any of the components\n* Platelet count less than 100,000\n* Weight less than 50Kg or over 100Kg\n* Any type of infectious disease (e. g, Endocarditis)\n* GFR less or equal to 15ml\u002Fmin\u002Fm2 or with renal replacement therapy\n* IV or oral contrast medium 72 hrs prior recruitment\n* LRA 7 days prior to surgery",{"count":91,"type":22},100,[62],"Acute kidney injury (AKI) associated with cardiac surgery is the most important complication in adult patients undergoing open heart surgery and is associated with increased mortality and morbidity. In patients in intensive care units, it is the second most common type of AKI after AKI secondary to sepsis. There is currently no specific treatment for AKI. Supportive measures include renal support therapy for patients with severe AKI, and mortality in this subgroup of patients exceeds 50%. Increasing NAD+ with niacinamide has been shown to prevent various etiologies of experimental AKI in mice, and an early pilot study has shown both increased NAD levels following administration of nicotinamide riboside with pterostilbene NPRT and the safety of niacinamide in patients undergoing cardiac surgery.",[95,96],"Acute Kidney Injury","Cardiac Valve Disease",[98,99,100,101,102,103,104,105,106],"Nicotinamide Riboside","NAD+","NADH","SIRT1","AKI","Cardiac surgery","TIMP-2","IGFBP7","NGAL","2024-07-24",{"date":109,"type":40},"2024-07-25",{"date":107,"type":22},{"date":112,"type":22},"2026-07-24",{"name":46,"class":47},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":123,"phases":4,"briefSummary":124,"conditions":125,"keywords":131,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":138,"leadSponsor":140,"locationsCount":48},"100555598","gastrointestinal-dysfunction-in-aortic-surgery-patients-100555598","NCT06514170","Gastrointestinal Dysfunction in Aortic Surgery Patients","Assessment of Gastrointestinal Dysfunction Through GIDS Scale and Intestinal Damage Biomarkers in Critically Ill Patients Undergoing Aortic Surgery and Its Association With Clinical Outcomes.","Inclusion Criteria:\n\n* 18 years of age or older.\n* Patients after surgical interventions (elective or urgency) on the aorta with cardiopulmonary bypass.\n* Invasive mechanical ventilation expected to be required more than 48 hours.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients under mechanical ventilation with pre-existing gastrointestinal issues.\n* Diagnosis of adult congenital heart disease.\n* Ongoing pregnancy or lactation period.\n* Simultaneous participation in another clinical study involving experimental therapy.\n* Presence of chronic intestinal disease.\n* Previous gastrointestinal conditions detected during nutritional screening.",{"count":122,"type":22},114,"OBSERVATIONAL","The goal of this observational study is to determine the association of gastrointestinal dysfunction through the Gastrointestinal Dysfunction Scale (GIDS) tool and serum concentrations of citrulline and Intestinal fatty-acid binding protein (I-FABP) with primary \\[calories received, protein received, parenteral nutrition requirement and 28-day mortality in the intensive care unit (ICU)\\] and secondary (development of pneumonia, surgical and cardiovascular complications in the ICU, length of hospital and ICU stay, duration of mechanical ventilation) clinical outcomes in critically ill patients undergoing aortic surgery.",[126,127,128,129,130],"Aortic Aneurysm","Gastrointestinal Dysfunction","Aortic Diseases","Enteral Feeding Intolerance","Surgical Complication",[132,133,134],"Gastrointestinal dysfunction","Aortic diseases","Aorta surgery","2024-07-23",{"date":107,"type":40},{"date":135,"type":40},{"date":139,"type":22},"2026-06",{"name":46,"class":47},""]